SCHEMBL29514736

SCHEMBL29514736

O=C1CCCc2c(Br)cccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.53
PARP11 Q9NR21 1/20 0.53
HSD17B10 Q99714 2/20 0.50
KDM4E B2RXH2 1/20 0.50
CYP2A6 P11509 1/20 0.48
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
PIM1 P11309 1/20 0.47
CSNK1A1 P48729 1/20 0.47
CDK5 Q00535 1/20 0.47
ROCK1 Q13464 1/20 0.47
DYRK1A Q13627 1/20 0.47
LRRK2 Q5S007 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
DYRK1B Q9Y463 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.40
BRD4 O60885 2/20 0.39
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
HTR1A P08908 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1661783 1.00 PARP10 (0.53) PARP10PARP11HSD17B10KDM4ECYP2A6
SCHEMBL7920173 0.96 PARP10 (0.53) PARP10PARP11HSD17B10KDM4ECYP2A6
SCHEMBL30003712 0.96 PARP10 (0.53) PARP10PARP11HSD17B10KDM4ECYP2A6
SCHEMBL28004728 0.93 PARP10 (0.47) PARP10PARP11HSD17B10KDM4ECYP2A6
SCHEMBL163925 0.88 PARP10 (0.56) PARP10PARP11HSD17B10KDM4ECYP2A6
SCHEMBL29429928 0.88 PARP10 (0.56) PARP10PARP11HSD17B10KDM4ECYP2A6
SCHEMBL28041457 0.83 MAOA (0.56) HSD17B10KDM4ECYP2A6MAOAMAOB
Methylamine SCHEMBL27811293 0.82 PARP10 (0.51) PARP10PARP11HSD17B10KDM4ECYP2A6
SCHEMBL29501042 0.78 PARP1 (0.55) PARP10PARP11KDM4ECYP2A6MAOA
SCHEMBL1151194 0.78 PARP1 (0.55) PARP10PARP11KDM4ECYP2A6MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120152713-A Tricyclic aryl derivatives and compositions and methods thereof 昂胜医疗科技公司 2025-06-13 CN disclosed
CN-115925697-B Small molecule immunoregulation inhibitor and pharmaceutical composition and application thereof 昆药集团股份有限公司 2025-05-09 CN disclosed
US-20250122152-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-04-17 US disclosed
CN-119731163-A KIF18A inhibitor compound, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2025-03-28 CN disclosed
CN-115867346-B Kinase inhibitors GB005股份有限公司 2025-03-14 CN disclosed
CN-119285479-A Preparation and application of novel MAO-B inhibitor containing tetrahydronaphthalene-1-amine structure 重庆医科大学 2025-01-10 CN disclosed
CN-118852123-A Novel heterocyclic compounds as Pol theta inhibitors for the treatment and prevention of cancer and pharmaceutical compositions containing the same 株式会社大熊制药 2024-10-29 CN disclosed
CN-113677659-B Substituted amide compounds useful as farnesoid X receptor modulators 百时美施贵宝公司 2024-09-06 CN disclosed
CN-118159537-A 6-Aza-quinoline derivatives and related uses 黑钻治疗公司 2024-06-07 CN disclosed
CN-117126151-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 CN disclosed
CN-117069712-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117069713-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117024420-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-10 CN disclosed
CN-116194456-A Preparation of heterocyclic compounds as KRAS inhibitors and methods of use thereof 上海科州药物研发有限公司 2023-05-30 CN disclosed
CN-115925697-A Small molecule immunoregulation inhibitor and pharmaceutical composition and application thereof 昆药集团股份有限公司 2023-04-07 CN disclosed
CN-115867346-A Kinase inhibitors GB005股份有限公司 2023-03-28 CN disclosed
WO-2022127827-A1 KRASG12C PROTEIN MUTATION INHIBITOR AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 上海维申医药有限公司 2022-06-23 WO disclosed
CN-114644631-A KRAS G12C protein mutation inhibitor, preparation method thereof, pharmaceutical composition and application thereof 上海维申医药有限公司 2022-06-21 CN disclosed
CN-114258390-A Glycolate oxidase inhibitors for disease treatment 生物马林药物股份有限公司 2022-03-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122152-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT7 PARP10 973/4885PARP11 1749/4885HSD17B10 672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.